ETC
CRBP icon

Exchange Traded Concepts’s Corbus Pharmaceuticals CRBP Stock Holding History

Exchange Traded Concepts’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,131
Closed -$208K – 1592
2026
Q1 		$208K Buy
+22,131
New +$186K ﹤0.01% 1227

Other funds holding CRBP

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Exchange Traded Concepts's CRBP Position: Q2 2026 in Review

Exchange Traded Concepts sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 22,131 shares — an estimated $208K sold.

Exchange Traded Concepts first reported a position in CRBP in Q1 2026 and held it in 1 quarter. The position peaked at $208K in Q1 2026. 14 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Exchange Traded Concepts reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Exchange Traded Concepts sold 22,131 Corbus Pharmaceuticals shares in Q2 2026, an estimated $208K.
  • Exchange Traded Concepts first reported a position in Corbus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Exchange Traded Concepts's Corbus Pharmaceuticals position peaked at $208K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.